Mo, Feiyan
Watanabe, Norihiro http://orcid.org/0000-0002-7678-0141
McKenna, Mary K.
Hicks, M. John
Srinivasan, Madhuwanti
Gomes-Silva, Diogo http://orcid.org/0000-0002-9615-3735
Atilla, Erden
Smith, Tyler
Ataca Atilla, Pinar
Ma, Royce
Quach, David
Heslop, Helen E.
Brenner, Malcolm K.
Mamonkin, Maksim http://orcid.org/0000-0001-7178-8163
Funding for this research was provided by:
Leukemia and Lymphoma Society (TRP #6566, TRP #6566, TRP #6566, TRP #6566)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5P50CA126752, 5P50CA126752, 5P50CA126752, 5P50CA126752, 5P50CA126752)
EIF | Stand Up To Cancer (604817, 604817, 604817, 604817)
Cancer Prevention and Research Institute of Texas (RP180810)
Article History
Received: 29 June 2019
Accepted: 10 June 2020
First Online: 13 July 2020
Competing interests
: H.E.H. is co-founder with equity: Allovir, Marker Therapeutics; advisory boards: Gilead, Tessa Therapeutics, Novartis, PACT Pharma, Kiadis Pharma; research funding: Tessa Therapeutics, Cell Medica. M.K.B. is co-founder with equity: Allovir, Marker Therapeutics, Tessa Therapeutics; advisory boards: Tessa Therapeutics, Unum, Allogene. D.Q.’s research funding: Tessa Therapeutics. M.M., F.M. and M.K.B. are co-inventors on a patent related to ADRs and methods of their use, licensed to Fate Therapeutics. All other authors report no relevant financial/nonfinancial interests.